Thelansis

Influenza B Market Outlook Thelansis’s “Influenza B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Influenza B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do interviewed...

  Influenza B Market Outlook Thelansis’s “Influenza B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Influenza B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Influenza B Overview Influenza B is a prevalent respiratory infection. Approximately 20-30% of diagnosed cases of influenza viral infections can be attributed to the influenza B virus. Similar to the influenza A virus, the influenza B virus belongs to the family Orthomyxoviridae. Both viruses possess segments 1, 3, 4, and 5, denoted as FLUA and FLUB, which encode a single protein per segment: PB2, PA, HA, and NP proteins. However, there are a few notable distinctions i...

  Influenza B is a prevalent respiratory infection. Approximately 20-30% of diagnosed cases of influenza viral infections can be attributed to the influenza B virus. Similar to the influenza A virus, the influenza B virus belongs to the family Orthomyxoviridae. Both viruses possess segments 1, 3, 4, and 5, denoted as FLUA and FLUB, which encode a single protein per segment: PB2, PA, HA, and NP proteins. However, there are a few notable distinctions in influenza B viruses. For instance, segment 2 of FLUAV encodes the polymerase subunit PB1. In certain strains, this segment may also encode a small accessory protein called PB1-F2, which exhibits apoptotic activity. Influenza B viruses are classified into two lineages: B/Yamagata and B/Victoria. Additionally, IFB viruses are further categorized into specific clades and sub-clades. The B/Victoria clades encompass V1A, while the subclades consist of V1A.1, V1A.2, and V1A.3. The B/Yamagata clades encompass Y1, Y2, and Y3, without any su...

 Influenza B is a prevalent respiratory infection. Approximately 20-30% of diagnosed cases of influenza viral infections can be attributed to the influenza B virus. Similar to the influenza A virus, the influenza B virus belongs to the family Orthomyxoviridae. Both viruses possess segments 1, 3, 4, and 5, denoted as FLUA and FLUB, which encode a single protein per segment: PB2, PA, HA, and NP proteins. However, there are a few notable distinctions in influenza B viruses. For instance, segment 2 of FLUAV encodes the polymerase subunit PB1. In certain strains, this segment may also encode a small accessory protein called PB1-F2, which exhibits apoptotic activity. Influenza B viruses are classified into two lineages: B/Yamagata and B/Victoria. Additionally, IFB viruses are further categorized into specific clades and sub-clades. The B/Victoria clades encompass V1A, while the subclades consist of V1A.1, V1A.2, and V1A.3. The B/Yamagata clades encompass Y1, Y2, and Y3, without any subcl...